B. Metzler seel. Sohn & Co. Holding AG Makes New $1.65 Million Investment in Cencora, Inc. (NYSE:COR)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the 3rd quarter, Holdings Channel.com reports. The fund purchased 7,320 shares of the company’s stock, valued at approximately $1,648,000.

Other institutional investors have also recently made changes to their positions in the company. Banque Cantonale Vaudoise increased its holdings in shares of Cencora by 11.0% during the 3rd quarter. Banque Cantonale Vaudoise now owns 23,024 shares of the company’s stock worth $5,182,000 after acquiring an additional 2,278 shares during the last quarter. Belmont Capital LLC increased its holdings in shares of Cencora by 91.4% during the 3rd quarter. Belmont Capital LLC now owns 88,350 shares of the company’s stock worth $19,886,000 after acquiring an additional 42,200 shares during the last quarter. Islay Capital Management LLC increased its holdings in shares of Cencora by 53.9% during the 3rd quarter. Islay Capital Management LLC now owns 11,861 shares of the company’s stock worth $2,670,000 after acquiring an additional 4,156 shares during the last quarter. TrinityPoint Wealth LLC acquired a new position in shares of Cencora during the 3rd quarter worth approximately $211,000. Finally, Thrivent Financial for Lutherans increased its holdings in shares of Cencora by 28.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 110,499 shares of the company’s stock worth $24,871,000 after acquiring an additional 24,492 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at $74,283,064.32. This represents a 6.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 15.80% of the stock is owned by corporate insiders.

Cencora Stock Performance

NYSE:COR opened at $245.02 on Friday. The stock has a fifty day moving average price of $233.12 and a 200-day moving average price of $231.47. The company has a market cap of $48.28 billion, a price-to-earnings ratio of 32.69, a PEG ratio of 1.60 and a beta of 0.44. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88. Cencora, Inc. has a fifty-two week low of $195.83 and a fifty-two week high of $251.56.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 29th. Investors of record on Friday, November 15th will be given a dividend of $0.55 per share. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Friday, November 15th. Cencora’s dividend payout ratio is currently 29.29%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on COR shares. Leerink Partners decreased their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a report on Monday, October 7th. JPMorgan Chase & Co. boosted their target price on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a report on Wednesday, August 21st. UBS Group boosted their target price on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Evercore ISI boosted their price target on Cencora from $250.00 to $285.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and a consensus price target of $271.20.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.